GlassScriptPhysician profile
Katherine Sandra Freeman
NPI 1770752594
$2,605.62
in general payments reported to CMS, 2019-2025
21 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $520 · 2021: $482 · 2022: $150 · 2023: $118 · 2024: $425 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $520.00 | 2020 | |
| Medtronic, INC. | $498.90 | 2021-2024 | Minimed 780g |
| Covidien LP | $371.51 | 2019 | |
| Novo Nordisk INC | $326.10 | 2022-2025 | Wegovy, Ozempic |
| Abbvie INC. | $169.68 | 2019-2024 | |
| Boston Scientific Corporation | $124.00 | 2019 | |
| Laborie Medical Technologies Corp. | $122.93 | 2024 | Alphaone |
| Abbott Laboratories | $65.58 | 2024-2025 | Freestyle Libre 3, Aveir, Mitraclip |
| Opko Pharmaceuticals, LLC | $64.35 | 2024-2025 | Rayaldee |
| Celgene Corporation | $63.13 | 2021-2023 | Zeposia |
| Genzyme Corporation | $55.90 | 2024-2025 | |
| Capsovision, INC. | $46.55 | 2024 | Capsocam Plus |
| Intuity Medical INC | $37.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $23.83 | 2024 | Zepbound, Jardiance |
| Conmed Corporation | $23.65 | 2025 | Conmed Biliary |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.81 | 2023 | Ibsrela |
| Janssen Biotech, INC. | $21.16 | 2025 | Tremfya |
| Rhythm Pharmaceuticals, INC. | $19.94 | 2025 | Imcivree |
| Philips North America LLC | $16.64 | 2024 | (Ck4) Mcot |
| Corcept Therapeutics | $11.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.